[
  {
    "criterion": "Provides a brief summary of the mechanisms of action for infliximab and etanercept in RA",
    "axis": "completeness",
    "point": 8
  },
  {
    "criterion": "Mentions the importance of assessing infection risk before switching biologics",
    "axis": "accuracy",
    "point": 5
  },
  {
    "criterion": "Asks the user what specifically they would like to know about switching therapy",
    "axis": "context_awareness",
    "point": 5
  },
  {
    "criterion": "Uses natural language and correct interpretation",
    "axis": "communication_quality",
    "point": 5
  },
  {
    "criterion": "Incorrectly states that infliximab and etanercept have identical mechanisms of action",
    "axis": "accuracy",
    "point": -9
  },
  {
    "criterion": "Fails to provide information on the importance of proper screening and prophylaxis for latent TB reactivation",
    "axis": "completeness",
    "point": -5
  },
  {
    "criterion": "Does not address the role of half-life in therapy choice",
    "axis": "completeness",
    "point": -3
  },
  {
    "criterion": "Provides a detailed explanation of the differences in half-life between infliximab and etanercept",
    "axis": "completeness",
    "point": 7
  },
  {
    "criterion": "Incorrectly states that infliximab is contraindicated in patients with latent TB",
    "axis": "accuracy",
    "point": -8
  },
  {
    "criterion": "Fails to provide a clear recommendation for bridging therapy",
    "axis": "completeness",
    "point": -4
  },
  {
    "criterion": "Correctly states that etanercept has a shorter half-life than infliximab",
    "axis": "accuracy",
    "point": 6
  }
]